Overview Of Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)

Researchmoz added Most up-to-date research on "Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)" to its huge collection of research reports.

The report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020), provides analysis of the global cancer diagnostics market and the US cancer diagnostics market, with detailed analysis of market size and growth, penetration and market share. The report also provides the analysis of the global and the US cancer market, by prevalence, new cases, deaths, type of cancers, etc. The report provides the market sizing of the global lung and breast cancer diagnostic market by value and by segments.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=841071

The report also discusses about the different diagnostic test of lung cancer and breast cancer. The diagnostics test analyzed in the report are: MetaStat (Meta Test) (Breast Cancer Test), OncotypeDX (Breast Cancer Test), OncoCyte (Lung Cancer Test), Veracytes Test (Lung Cancer Test) and Integrated Diagnostics, Inc. Test (Lung Cancer Test).

Country Coverage

North America (US)

Executive Summary

A disease caused by abnormal growth of cells in the body, is called Cancer. In this disease, the formation of new cells slows or start dividing, forming lumps. However, all lumps are not cancerous; and this can be known by diagnosis.

There are various types of cancer- prostate cancer, breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-hodgkin lymphoma, kidney and renal, pelvis cancer, thyroid cancer, endometrial cancer and others.

Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented.

The global cancer diagnostic market is expected to increase at a significant growth rate during the forecasted period (2016-2020). The global cancer diagnostic market is supported by various growth drivers, such as the rising incidence of cancer, sedentary lifestyle, growing technological advancement, increasing awareness, etc.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-cancer-diagnostic-market-with-focus-on-lung-and-breast-cancer-2016-2020-report.html/toc

1. Executive Summary

2. Introduction

2.1 Cancer Overview
2.2 Cancer Diagnostic: Overview
2.3 Cancer Diagnostic: Liquid Biopsy

3. Market Analysis

3.1 Cancer Prevalence Analysis
3.1.1 Global Cancer New Cases and Death
3.1.2 Global Cancer Prevalence, New Cases and Death by Type
3.1.3 US Cancer Prevalence
3.1.4 US Cancer New Cases and Death by Type

3.2 Cancer Diagnostic Market Analysis
3.2.1 Global Cancer Diagnostic Market by Value
3.2.2 Global Cancer Diagnostic Market by Segments (Type of Tests)
3.2.3 Global Cancer Diagnostic Market by Segments (Type of Cancer)
3.2.4 Global Cancer Diagnostic Market by Region
3.2.5 North America Cancer Diagnostic Market by Value

3.3 Lung Cancer Diagnostic Market Analysis
3.3.1 Global Lung Cancer Diagnostic Market by Value
3.3.2 Global Lung Cancer Diagnostic Market by Segment (Type of Test)
3.3.3 Global Lung Cancer Cases by Type

Continue...

Latest Research Report on Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies | Researchmoz

Researchmoz added Most up-to-date research on "Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies" to its huge collection of research reports.

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=751801

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

Scope

The hematological cancers market is characterized by commercially successful therapies.

- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/frontier-pharma-hematological-cancers-highly-innovative-pipeline-continues-trend-towards-targeted-patientspecific-therapies-report.html/toc

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
- Which molecular targets appear most frequently in the pipeline?
- To what degree is the pipeline penetrated by first-in-class innovation?
- Which target families have the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.

- How well are first-in-class targets aligned to known disease-causing pathways?
- Which targets are specifically found in early-stage development?
- Which are the most promising first-in-class targets in early-stage development?

There have been 284 licensing deals and 238 co-development deals pertaining to hematological cancer products since 2006.

- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
- Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that are not yet involved in deals, and may be potential investment opportunities. 

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=751801

Non-Small Cell Lung Cancer (NSCLC) Asia-Pacific Market Will Be Valued At $6.2 Billion In 2023, At A CAGR Of 10.8%

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1049126

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the firstand second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted towards EGFR T790M are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS abemaciclib is being developed in the pipeline.

Make an Enquiry of this report @ https://www.researchmoz.us/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-report.html/toc

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

- How will immunotherapies such as atezolizumab contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
- The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
- Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1049126

Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021) - Johnson & Johnson, AstraZeneca, AbbVie, Roche

Researchmoz added Most up-to-date research on "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=964493

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Increasing Obesity
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.1.6 Global Spending on Medicines
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.2 CDK4/6 Inhibitors Under Clinical Trials for Breast Cancer
4.2.3 Introduction of Newer Imaging Tests
4.3 Challenges
4.3.1 Long Term Side Effects
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Heavy Drug Developmental Costs

5. Competition
5.1 Revenue Comparison
5.2 Research & Development Expenditure Comparison
5.3 Market Cap Comparison

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AbbVie
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Roche
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Browse Detail Report With TOC @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html

Pain Management Therapeutics Market Will Exhibit A 3.7% CAGR Over The Period Between 2016 And 2024 Expected To Rise To US$83.0 bn

Researchmoz added Most up-to-date research on "Pain Management Therapeutics Market (Therapeutics - Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDS), Opioids (Oxycodones, Hydrocodones, Tramadol), Antimigraine Agents, Other Non-narcotic Analgesic; Indication - Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine, Post-operative Pain, Cancer Pain) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2023" to its huge collection of research reports.

This report on the pain management therapeutics market studies the current as well as future prospects of the market globally. The pain management therapeutics market report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the general information and data analysis of the global pain management therapeutics market with respect to the leading market segments based on major therapeutics, and geographies.

The global pain management therapeutics market has been studied based on major segments by therapeutics, by indication and their regional as well as national markets. Based on therapeutics, the global market has been segmented into anticonvulsants, antidepressants, anesthetics, non-steroidal anti-inflammatory drugs (NSAIDS), opioids, other non-narcotic analgesic, and antimigraine agents. Further the market has been segmented according to its indication that includes neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain, and cancer pain. The market for these segments has been extensively analyzed based on their effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=816197

The market overview section of the report explores the dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the pain management therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the overview section in order to explain the intensity of competition across different geographies. The competitive scenario among different players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their position and expand their shares in the global pain management therapeutics market.

Geographically, the pain management therapeutics market has been segmented into four regions: North America, Europe, Asia Pacific, and Rest of the World(RoW). Each regional pain management therapeutics market has been further categorized into major national markets such as the U.S, Canada, Germany, the U.K., Japan, China, Brazil, and Mexico. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.

The recommendations section included in the report would assist existing market players to expand their market shares, and new companies in establishing their presence in the global pain management therapeutics market. The report also profiles key players operating in this market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Abbott Laboratories, AstraZeneca, Depomed, Inc., Endo Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Purdue Pharma L.P., and Teva Pharmaceutical Industries Limited.

The global pain management therapeutics market is segmented as follows:

Global Pain Management Therapeutics Market Revenue, by Therapeutics
- Anticonvulsants
- Antidepressants
- Anesthetics
- Non-steroidal Anti-inflammatory Drugs (NSAIDS)
- Opioids
- Oxycodones
- Hydrocodones
- Tramadol
- Others (Morphine, Codeine, Fentanyl, Meperidine, Methadone)
- Antimigraine Agents
- Other Non-narcotic Analgesic

Global Pain Management Therapeutics Market Revenue, by Indication

- Neuropathic Pain
- Fibromyalgia
- Chronic Back Pain
- Arthritic Pain
- Migraine
- Post-operative Pain
- Cancer Pain

Global Pain Management Therapeutics Market, by Geography

- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific (APAC)
- China
- Japan
- Rest of the World (RoW)
- Brazil
- Mexico

Browse Detail Report With TOC @ https://www.researchmoz.us/pain-management-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2016-2023-report.html

Global Patient Registry Software Market Is Expected To Expand Its Revenue Generation At A CAGR Of 10.5% Between 2015 And 2023 Touch Nearly US$2 bn

Researchmoz added Most up-to-date research on "Patient Registry Software Market (By Type - Public Domain Registry Software, Commercial Registry Software; By Disease Areas - Diabetes Registry, Cardiovascular Registry, Cancer Registry, Rare Disease/Orphan Disease Registry, Other Chronic Disease Registry; By End-User - Government, Commercial) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" to its huge collection of research reports.

This report on the global patient registry software market provides an analysis for the period 2013 - 2023, wherein 2014 is the base year and the period from 2015 to 2023 is the forecast period. Data for 2013 has been included as historical information. The report covers all the prevalent trends and technologies playing a major role in the growth of the patient registry software market over the forecast period. It also highlights various drivers, restraints, and opportunities expected to influence the market growth during the said period. The study provides a holistic perspective on market growth, throughout the above forecast period in terms of revenue estimates (in US$ Mn), across different geographies, which include North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and Latin America (LATAM).

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=506463

Patient registries are the computerized databases that contain personal, medical, social, and financial data being reported by healthcare professionals and patients. For rare or chronic diseases, registries can provide vital epidemiological data such as incidence and prevalence, symptoms, and severity of the disease to researchers and healthcare professionals. Due to the continuous growth of chronic diseases, population and disease management is highly needed, which in turn drives the overall demand for patient registry software. The growing demand for patient registry software has led to the emergence of patient registry software vendors around the world, which has contributed to the growth of market size globally.

This research report provides in-depth analysis of the global patient registry software market on the basis of software types, disease areas, and end-users. The patient registry software types are public domain and commercial. The patient registry software on the basis of disease areas is divided into diabetes registry, cardiovascular registry, cancer registry, rare disease/orphan disease registry, and other chronic disease registry. The patient registry software end-user segment comprises government and commercial segments.

In terms of geographical regions, the report segments the global patient registry software market into North America, Europe, Asia Pacific, Middle East & Africa (MEA), and Latin America; the regions are analyzed in terms of revenue generation. The report provides cross-sectional analysis of the global patient registry software market in terms of market estimates and forecasts for all segments across different geographic regions.

The report also includes competitive profiling of major players engaged in developing patient registry software. Major business strategies adopted by them, their market positioning, and various recent developments have also been identified in the research report. This report also provides market share analysis of major players in the patient registry software market based on their 2014 revenues. Some of the major players profiled in the report include Global Vision Technologies, Inc., Quintiles Inc., Dacima Software Inc., PatientCrossroads, and Evado eClinical Solutions.

Browse Detail Report With TOC @ http://www.researchmoz.us/patient-registry-software-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html

The global patient registry software market is segmented as below:

Patient Registry Software Market 

By Type

- Public Domain Registry Software
- Commercial Registry Software

By Disease Areas

- Diabetes Registry
- Cardiovascular Registry
- Cancer Registry
- Rare Disease/Orphan Disease Registry
- Other Chronic Disease Registry

By End-User

- Government
- Commercial

By Geography

- North America
- U.S.
- Rest of North America
- Europe
- EU7 Countries
- CIS Countries
- Rest of Europe
- Asia Pacific
- Japan
- China
- South Asia
- Australasia
- Rest of APAC
- Middle East and Africa
- GCC Countries
- North Africa
- South Africa
- Rest of MEA
- Latin America
- Brazil
- Rest of Latin America

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=506463

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast 2023

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1049126

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the firstand second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted towards EGFR T790M are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS abemaciclib is being developed in the pipeline.

Browse Detail Report With Full TOC @ http://www.researchmoz.us/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-report.html

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

- How will immunotherapies such as atezolizumab contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
- The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
- Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1049126

Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020) | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)" to its huge collection of research reports.

The report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020), provides analysis of the global cancer diagnostics market and the US cancer diagnostics market, with detailed analysis of market size and growth, penetration and market share. The report also provides the analysis of the global and the US cancer market, by prevalence, new cases, deaths, type of cancers, etc. The report provides the market sizing of the global lung and breast cancer diagnostic market by value and by segments.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=841071

The report also discusses about the different diagnostic test of lung cancer and breast cancer. The diagnostics test analyzed in the report are: MetaStat (Meta Test) (Breast Cancer Test), OncotypeDX (Breast Cancer Test), OncoCyte (Lung Cancer Test), Veracytes Test (Lung Cancer Test) and Integrated Diagnostics, Inc. Test (Lung Cancer Test).

Country Coverage

North America (US)

Executive Summary

A disease caused by abnormal growth of cells in the body, is called Cancer. In this disease, the formation of new cells slows or start dividing, forming lumps. However, all lumps are not cancerous; and this can be known by diagnosis.

There are various types of cancer- prostate cancer, breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-hodgkin lymphoma, kidney and renal, pelvis cancer, thyroid cancer, endometrial cancer and others.

Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented.

The global cancer diagnostic market is expected to increase at a significant growth rate during the forecasted period (2016-2020). The global cancer diagnostic market is supported by various growth drivers, such as the rising incidence of cancer, sedentary lifestyle, growing technological advancement, increasing awareness, etc.

Browse Detail Report With Full TOC @ http://www.researchmoz.us/global-cancer-diagnostic-market-with-focus-on-lung-and-breast-cancer-2016-2020-report.html

Table Of Content

1. Executive Summary

2. Introduction
2.1 Cancer Overview
2.2 Cancer Diagnostic: Overview
2.3 Cancer Diagnostic: Liquid Biopsy

3. Market Analysis

3.1 Cancer Prevalence Analysis
3.1.1 Global Cancer New Cases and Death
3.1.2 Global Cancer Prevalence, New Cases and Death by Type
3.1.3 US Cancer Prevalence
3.1.4 US Cancer New Cases and Death by Type

3.2 Cancer Diagnostic Market Analysis
3.2.1 Global Cancer Diagnostic Market by Value
3.2.2 Global Cancer Diagnostic Market by Segments (Type of Tests)
3.2.3 Global Cancer Diagnostic Market by Segments (Type of Cancer)
3.2.4 Global Cancer Diagnostic Market by Region
3.2.5 North America Cancer Diagnostic Market by Value

3.3 Lung Cancer Diagnostic Market Analysis
3.3.1 Global Lung Cancer Diagnostic Market by Value
3.3.2 Global Lung Cancer Diagnostic Market by Segment (Type of Test)
3.3.3 Global Lung Cancer Cases by Type

3.4 Breast Cancer Diagnostic Market Analysis
3.4.1 Global Breast Cancer Diagnostic Market by Value

3.5 MetaStat (Meta Test) Analysis (Breast Cancer Test)
3.5.1 Mena Testing: An Overview
3.5.2 Mena Breast Cancer Test Market Opportunity (US)
3.5.3 US Mena Test Market Opportunity
3.5.4 US Mena Test Market by Number of Test and Addressable Population

3.6 OncotypeDX (Breast Cancer Test)
3.6.1 OncotypeDX by Addressable Market

3.7 OncoCyte (Lung Cancer Test)
3.7.1 OncoCyte Test by Average Price and Revenue
3.7.2 OncoCyte Test by Test Volume and Market Penetration

3.8 Veracytes Test (Lung Cancer Test)
3.8.1 Veracytes Percepta Test Overview

3.9 Integrated Diagnostics, Inc. Test (Lung Cancer Test)
3.9.1 Integrated Diagnostics, Inc. Test Overview

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=841071

Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 – Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" to its huge collection of research reports.

DelveInsights Report, Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Non-Small Cell Lung Cancer Report is to understand the market and pipeline status of the drugs around the Non-Small Cell Lung Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsights Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Non-Small Cell Lung Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=917773

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
A snapshot of the global Market and Phase III therapeutics scenario for Non-Small Cell Lung Cancer.
A review of the marketed products under prescription for Non-Small Cell Lung Cancer, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Non-Small Cell Lung Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Non-Small Cell Lung Cancer drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Non-Small Cell Lung Cancer drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Non-Small Cell Lung Cancer drugs.
Coverage of Non-Small Cell Lung Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure to 2018.

Browse Detail Report With Full TOC @ http://www.researchmoz.us/non-small-cell-lung-cancer-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2017-report.html

Reasons to buy

Evaluate the marketing status and exclusivity details of Non-Small Cell Lung Cancer key products to exploit opportunities for generic drug development opportunities.

Identify and understand important and diverse types of therapeutics under Phase III development for Non-Small Cell Lung Cancer.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Non-Small Cell Lung Cancer.

API intelligence over marketed drugs forNon-Small Cell Lung Cancerand gaining primary intelligence over active ingredients manufacturers across the globe.

API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Non-Small Cell Lung Cancer.
Uncovering opportunities in the rapidly growing US market.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=917773

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024 - Researchmoz

Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports.

Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=699490

For the purposes of this report, GlobalData considers the Global SCLC market to include SCLC-specific drug sales in the 7MM (US, 5EU [France, Germany Italy, Spain, and the UK], and Japan). The current market across these countries is dominated by the sale of major generic chemotherapy regimens. GlobalData estimated that the Global SCLC market was valued at $198m in 2014. Following the expected approval of new agents over the forecast period, relapsed/refractory patients will have significantly improved therapeutic options leading to rapid uptake of these drugs. The increased use of branded therapies in treatment-nave and advanced patients, such as Yervoy, Opdivo, roniciclib, and sacituzumab govitecan, will be the primary driver of the substantial growth in the SCLC market over the forecast period, which is expected to grow at a positive CAGR of almost 28% in the 7MM.

Highlights

Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the SCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?
- What research and development (R&D) strategies will companies leverage to compete in the future SCLC marketplace?
- Which pipeline products are poised to make a major clinical and commercial impact?
- What clinical and commercial factors are likely to influence SCLC drug uptake in the 7MM?

Key Findings

- The greatest driver of growth within the Global SCLC market will be the launch and increased use of premium-priced therapies, including anti-PD-1 immunotherapy and targeted agents such as roniciclib and sacituzumab govitecan. GlobalData expects Yervoy to reach blockbuster status by the end of the forecast period, with global sales of around $1bn.
- Continuous dosing regimens until disease progression and adoption of maintenance setting following induction therapy for first-line patients will contribute to the increased sales of branded drugs.
- Toxicity is likely to remain a major concern as new first-line treatment options are approved considering companies are developing them in combination with platinum-etoposide. Therefore, substantial opportunity remains to develop therapies that have improved safety profiles compared with agents in the current SCLC pipeline.
- An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of SCLC pipeline agents. GlobalData expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new SCLC therapies.

Scope

- Overview of SCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Topline SCLC drug market revenue from 2014-2024, annual cost of therapy (ACOT), and major product sales in six patient segments during the forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the SCLC market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global SCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SCLC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=699490

Global Breast Cancer Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2015

Researchmoz added Most up-to-date research on "Global Breast Cancer Market Report: 2015 Edition" to its huge collection of research reports.

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=315089

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table Of Content

1. Market Overview1.1 Breast Cancer
1.2 Types of Breast Cancer
1.3 Risk Factors
1.4 Symptoms of Breast Cancer
1.5 Diagnosis and Treatment of Breast Cancer
1.5.1 Breast Cancer Screening and Diagnostic Measures
1.5.2 Breast Cancer Treatment

2. Breast Cancer Market
2.1 Global Market

- Diagnostics Market
- Therapeutic Market
- Market Segmentation

3. Regional Markets
3.1 The U.S. Breast Cancer Market
3.1.1 The U.S. Breast Cancer Diagnostics Market
3.1.2 The U.S. Breast Cancer Therapeutic Market
3.1.3 The U.S. Metastatic Breast Cancer Market
3.2. Brazilian Breast Cancer Market
3.2.1 Brazilian Breast Cancer Diagnostic Market
3.2.2 Brazilian Breast Cancer Therapeutic Market
3.3 APAC Countries
3.3.1 APAC Diagnostic Market
3.3.2 APAC Therapeutic Market
3.4 European Breast Cancer Market
3.4.1 European Breast Cancer Diagnostic Market
3.4.2 European Metastatic Breast Cancer Market

4. Market Dynamics
4.1 Industry Developments
4.1.1 Introduction of New Drugs & Therapies
4.1.2 Development of Scintimammography for Molecular Breast Imaging
4.1.3 Compounds under Study to Reduce Breast Cancer
4.1.4 Researches on DCIS Prediction
4.2 Growth Drivers
4.2.1 Increasing Use of Tobacco and Alcohol
4.2.2 Increasing Diabetic and Obese Population Worldwide
4.2.3 Rising Healthcare Expenditure
4.2.4 Growing Women Population (Over 45 Years)
4.2.5 Increasing Global Spending on Medicines
4.2.6 Dense Breast Tissue
4.2.7 Exposure to X-Ray and Gamma Radiations
4.2.8 Estrogen-Progestin Therapy (EPT)
4.3 Challenges
4.3.1 Financial Burden of Breast Cancer
4.3.2 Adverse Effects of Aromatase Inhibitors (AI)

5. Competitive Landscape

- Comparison of Drugs
- Net Income
- R&D Budget

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=315089

Global Cancer Immunotherapy Market Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024

Researchmoz added Most up-to-date research on "Cancer Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its huge collection of research reports.

The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market.

The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region. Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=910648

Global Cancer Immunotherapy Market: Trends and Drivers

The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years.

However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market. With many types and subtypes of cancer, having a single mode of treatment method is impossible, increasing the attrition rates of new drugs and treatments. Only a handful of contenders in the pipeline pass through the phase III trials and the rest are considered to be inefficient. This is yet another challenge faced by players in the market.

Global Cancer Immunotherapy Market: Segmentation

On the basis of therapeutic area, the market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. By end users, the global cancer immunotherapy market is segmented into ASC’s (ambulatory surgical centers), hospitals, clinics, and cancer research centers. Hospitals are expected to be the leading segment in the market. On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Asia Pacific is poised to witness significant growth in the market.

Key Players Mentioned in this Report are:

The report provides studies key players operating in the market. Some of the key players in the global cancer immunotherapy market are: F.Hoffmann-La Roche Ltd., AstraZenca Plc, Eli Lilly and Company, Amgen, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Janssen Biotech, Inc., Merck & Co., Inc., Sanofi, Takeda Pharmaceuticals, and Spectrum Pharmaceuticals, Inc.

The report segments the global cancer immunotherapy market as:

By Geography:

- North America
- Asia Pacific
- Europe
- Rest of the World

This report gives you access to decisive data such as:

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years

Key highlights of this report

- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=910648

New Survey on Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 | Researchmoz

Researchmoz added Most up-to-date research on "Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" to its huge collection of research reports.

GlobalData's Medical Devices sector report, Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=895916

Scope

- Extensive coverage of the Lung Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=895916

At A CAGR Of 15.17% Global Cancer Immunotherapies Market To Grow During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Cancer Immunotherapies Market 2016-2020" to its huge collection of research reports.

Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.

Technavios analysts forecast the global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=715922

Technavio's report, Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Takeda Pharmaceuticals

Other prominent vendors
AbbVie
ADC Therapeutics
Agensys
Astellas
AstraZeneca
Bayer
Biogen
Biotech Pharmaceutical
Boehringer-Ingelheim
Celgene
Celldex Therapeutics
Chugai Pharmaceutical
CTI Biopharma
Daiichi Sankyo
Eli Lilly
Fortress Biotech
Genmab
Immunomedics
Intas Pharmaceuticals
Janssen Biotech
Kyowa Hakko Kirin
MedImmune
Morphotek
Neovii Biotech
Novartis
OncoMed Pharmaceuticals
Pfizer
Sanofi
Seattle Genetics
Spectrum Pharmaceuticals
TG Therapeutics
XBiotech

Market driver
Increase in demand for cancer monoclonal antibodies
For a full, detailed list, view our report

Market challenge
Patent expiry of top-selling drugs
For a full, detailed list, view our report

Market trend
Emergence of targeted and combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=715922

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2023

Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1049126

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the firstand second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted towards EGFR T790M are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS abemaciclib is being developed in the pipeline.

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

- How will immunotherapies such as atezolizumab contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
- The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
- Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1049126

Researchmoz: Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

Researchmoz added Most up-to-date research on "Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets" to its huge collection of research reports.

The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. Instead of extending a patient’s life expectancy, the emphasis is on improving overall quality of life. The key indications covered in this report are cancer pain, oral mucositis, chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV) and bone metastasis. These indications are not only distressing for patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise.

The majority of indications targeted by cancer supportive care products are the direct result of a patient receiving chemotherapy in an attempt to cure their cancer or relieve symptoms. It is often the case that the most effective chemotherapy regimens result in the most severe symptoms. This increases the need for cancer supportive care products, which can improve patient outcomes by providing greater tolerance to the most effective regimens. Bone metastasis and most forms of cancer pain are not caused by chemotherapy or cancer treatment, and are instead often a symptom of the cancer itself, occurring in a high proportion of cancer patients.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1065936

The level of unmet need within the cancer supportive care therapy area varies between indications. CIN and CINV both already have treatment regimens that can significantly decrease the incidence rate. However, the level of unmet need for CIA, cancer pain, oral mucositis and bone metastasis is high, with treatment focusing heavily on alleviating the symptoms instead of treating the underlying cause.

There are 245 products in active development in the cancer supportive care pipeline, but this includes products in development for smaller and less commercially significant indications. There are 169 products in active development for the key indication examined in this report, giving an average of 28 products per indication, the majority of which are at an early stage of development.

Scope

The cancer supportive care market already contains some commercially successful products.

- Which classes of drug dominate the market?
- Which indication is the most commercially successful?
- How will commercially successful drugs perform over the forecast period?

The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.

- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?

The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.

- Which products are forecast to drive growth?
- Will generic and biosimilar competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

- What are the leading companies in terms of market share?
- Which companies are forecast to experience the greatest growth in market share?
- What are the drivers of growth for key companies in the market?
- How dependent are the key companies on this disease cluster for revenue?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report
- Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis illustrates how dependent the key companies in the market are on revenue derived from cancer supportive care products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Identify commercial opportunities in the cancer supportive care deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1065936

Global Cancer Vaccines Market to 2022 New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Researchmoz added Most up-to-date research on "Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19" to its huge collection of research reports.

Cancer vaccines are being developed as a method of preventing certain types of cancer, and as therapeutic treatments to treat existing cancers across a range of indications in oncology, either as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery. The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies, which have a lower toxicity associated with their use than traditional chemotherapies. Therapeutic vaccine administration will increase the overall survival of poor-performance-status patients, and enable more rounds of treatment to be given – factors that will contribute to growing global revenues for this class of therapy. However, cancer vaccines are not perceived as having strong commercial potential, as immune checkpoint inhibitors are expected to dominate the treatment landscape for leukemia and lymphoma during the forecast period.

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive cancer prevalence and revenue growth for its treatments.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=879381

Prophylactic vaccines are currently used to immunize against viruses, which have been shown to increase the risk of cancer, with viral factors being the underlying cause of approximately 15% of cancers worldwide. Prophylactic vaccines such as Gardasil are currently the most commercially successful and well-established class of cancer vaccines. However, there has been a shift towards the clinical testing of therapeutic vaccines – which constitute the majority of the pipeline – such as Imlygic, which was recently approved for melanoma.

Scope

- Global revenues for the cancer vaccines market are forecast to grow at a compound annual growth rate (CAGR) of 16.93%, from $2.5 billion in 2015 to $7.5 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The cancer vaccine pipeline is large and fairly diverse, and contains 1,286 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular molecule types and molecular targets in the pipeline?
- What mechanisms of action and molecule types are most common for pipeline vaccines being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 pharma companies compare within cancer vaccines?
- What proportion of the key players’ revenues will be attributable to cancer vaccines?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the cancer vaccines market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the cancer vaccine pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the cancer vaccine market globally and across the key players and product types  
- Stratify the market in terms of the split between therapeutic and prophylactic vaccines, and assess the role of these product types in the treatment of the various cancers
- Identify commercial opportunities in the cancer vaccine deals landscape by analyzing trends in licensing and co-development deals

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=879381

Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021) | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=964493

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Increasing Obesity
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.1.6 Global Spending on Medicines
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.2 CDK4/6 Inhibitors Under Clinical Trials for Breast Cancer
4.2.3 Introduction of Newer Imaging Tests
4.3 Challenges
4.3.1 Long Term Side Effects
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Heavy Drug Developmental Costs

5. Competition
5.1 Revenue Comparison
5.2 Research & Development Expenditure Comparison
5.3 Market Cap Comparison

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AbbVie
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Roche
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=964493

Recent Study on Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Researchmoz added Most up-to-date research on "Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation" to its huge collection of research reports.

Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. In the US and EU, the annual incidence was estimated to be three to four cases per 100,000 people. GBM has a high degree of intratumoral heterogeneity, which is associated with poor prognosis and the development of drug resistance.

The GBM market is characterized by a small selection of marketed product options, consisting of chemotherapies, cancer immunotherapies and receptor tyrosine kinase inhibitor products. The pipeline is moderately large, with 512 products active across all stages of development. First-in-class products only constitute approximately a quarter of the pipeline, and represent 31% of products with a disclosed target. The most widely studied group of first-in-class targets are the receptor tyrosine kinase and ligand inhibitors, a trend that has been heavily influenced by the success of Avastin, and possibly successful EGFR inhibitors such as Tarceva that are used in the treatment of other oncology indications.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=826604

Potential driving factors for the market include a typically poor outcome for treated patients, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market, and a strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fulfill the unmet needs.

Overall, due to the highly complex and polygenic nature of GBM, which has numerous subtype classifications, it is unlikely that the inhibition of a single target will be sufficient to substantially improve patient prognosis. Instead, it is more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, may improve treatment outcomes. First-in-class targets analyzed in this report have shown encouraging efficacy profiles, and some show the ability to chemosensitize cancer cells.

Scope

- The report analyzes innovation in GBM, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products, and pinpoints opportunities for in-licensing.
- A brief introduction to GBM, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, including particular focal points of innovation in the pipeline.
- A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for GBM therapies.

Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options.
- Visualize the composition of the GBM market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the GBM pipeline, stratified by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the GBM deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=826604